EMX-001: Lead programme
Our lead development programme is a universal Flavivirus vaccine candidate, EMX-001, which is cross reactive against Zika, Dengue and Yellow Fever.
EMX-001 will start a Phase I clinical trial in Q1 2019.
We have a pipeline of vaccine candidates in preclinical development.
Development programmes
We also have programmes in development for a universal Filovirus vaccine, to target Ebola and Marburg, as well as a vaccine that potentially can target the outbreak of a new pandemic strain of flu at the time it moves from an animal species into humans.
Early-stage programmes
We are also in the process of initiating earlier-stage programmes for meningitis and bacterial pneumonia.
